Thomson J, Oswald I
Br Med J. 1977 Nov 19;2(6098):1317-9. doi: 10.1136/bmj.2.6098.1317.
A double-blind controlled study of the effect of piperazine oestrone sulphate on sleep, depression, anxiety, and hot flushes was performed in 34 perimenopausal women. Half of the patients were given six weeks' placebo followed by eight weeks' oestrogen, and half remained on placebo throughout. Sleep was recorded electrophysiologically every week, and mood and anxiety were rated daily by means of visual analogue scales. Hot flushes were counted daily. Observer rating scales of anxiety and depression were complete at intervals. During the first month of active treatment the amount of intervening wakefulness in the first six hours of sleep decreased significantly more in the oestrone group than in those on placebo. Between the baseline period and the second treatment month the oestrone group showed a significantly greater decrease in the total amount of intervening wakefulness and in the frequency of awakenings. Their total amount of rapid eye movement sleep increased. Mood and anxiety improved and the number of hot flushes decreased to a similar degree in both groups. Although oestrogen did reduce the number of episodes of wakefulness in perimenopausal women complaining of insomnia, its effects on their psychological symptoms were little different to those of placebo.
对34名围绝经期女性进行了一项关于硫酸哌嗪雌酮对睡眠、抑郁、焦虑和潮热影响的双盲对照研究。一半患者先服用六周安慰剂,然后服用八周雌激素,另一半则全程服用安慰剂。每周通过电生理记录睡眠情况,每天通过视觉模拟量表对情绪和焦虑进行评分。每天统计潮热次数。定期完成焦虑和抑郁的观察者评定量表。在积极治疗的第一个月,雌酮组睡眠前六个小时的中间觉醒时间减少量明显多于服用安慰剂的组。在基线期和第二个治疗月之间,雌酮组中间觉醒的总量和觉醒频率的下降幅度明显更大。她们的快速眼动睡眠总量增加。两组的情绪和焦虑都有所改善,潮热次数减少程度相似。尽管雌激素确实减少了主诉失眠的围绝经期女性的觉醒次数,但其对她们心理症状的影响与安慰剂的影响几乎没有差别。